At this year’s Interphex, the conversation around biomanufacturing was less about distant possibilities and more about practical execution. For Meg Carr, VP General Manager at Ecolab, the strongest themes were clear: contamination control must become more proactive, AI and automation must prove their value in regulated environments, and future-ready facilities must be flexible enough to adapt as pipelines, regulations, and capacity demands evolve.
In this post-show interview, Carr discusses the pressures shaping biopharma manufacturing today – and what companies need to prioritize as they build, expand, and modernize their operations.
What key trends or themes stood out at Interphex this year?
Interphex reinforced that the industry is moving from “big ideas” to practical execution. A few themes stood out.
First, AI and automation are becoming more grounded. The conversation has shifted from hype to where these tools are already improving reliability, strengthening quality oversight, and supporting operators in regulated environments.
Second, contamination control and cleaning innovation remain centre stage. As manufacturers push for higher utilisation and faster changeovers, they need approaches that are consistent, repeatable, and scalable, because uptime and quality depend on it.
Third, next-generation bioprocessing and sustainability are converging around the same business outcomes. The focus is higher productivity, less waste, and better cost performance, while still making real progress on sustainability commitments.
And finally, facility strategy is evolving. Flexible, modular thinking is gaining momentum, particularly where manufacturers want to unlock capacity within existing footprints and stay resilient as pipelines shift.
What is the biggest current constraint in biopharma contamination control, and how is it being addressed?
One of the biggest constraints in biopharma contamination control today is the growing gap between increasing process complexity and the way contamination risks are still managed in many facilities. As manufacturers move toward advanced biologics, multi‑product operations and higher facility utilisation, traditional, procedure‑driven approaches to contamination control are being pushed beyond their limits.
This challenge is becoming even more acute against the backdrop of unprecedented investment in new biopharma manufacturing capacity, particularly in the US. With hundreds of billions of dollars committed to greenfield builds and major expansions, there is intense pressure to bring facilities online quickly and operate them efficiently from day one.
From what I see across the industry, contamination risk is no longer confined to cleanroom grades or single unit operations. It spans facility design, material and personnel flows, cleaning strategies and day‑to‑day execution. Regulators are reinforcing this shift, placing greater emphasis on whether contamination risks are truly designed out and controlled proactively, rather than managed reactively through monitoring and deviation response.
The way this constraint is being addressed is through more holistic contamination control strategies. Leading manufacturers are embedding contamination considerations earlier into facility and process design, recognising that with the scale of investment and number of new sites coming online, early decisions must support long‑term reliability, uptime and regulatory confidence at scale.
What will define a “future-ready” biomanufacturing process or facility?
A future-ready facility is less about any single technology and more about adaptability, compliance and consistent performance over time. The question is: can you absorb and manage change without disruption, whether that change comes from new modalities, new regulations, or shifting demand?
That starts with designing for flexibility and risk-based control from day one. We’re seeing more emphasis on modular strategies, right-sized cleanroom approaches, and integrated contamination control that supports both quality and operational efficiency.
Digital readiness matters too, but in a practical way. It underpins visibility, data integrity and faster decision-making, helping teams reduce variability and identify risk earlier, without adding complexity for the sake of it.
Ultimately, as we witness the increase in investment and new facilities, future-ready sites should build resilience into daily operations, including sustainability and change management, so they can stay reliable, audit-ready, and efficient as the industry evolves.
Newsletters
Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.
